(Q36491819)

14 August 2017

1 reference

title

Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations (English)

1 reference

14 August 2017

1 reference

George Aperis

1

1 reference

PubMed ID

16732713

14 August 2017

Eleftherios Mylonakis

series ordinal

2

1 reference

PubMed ID

16732713

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Investigational Drugs

14 August 2017

1 reference

14 August 2017

15

1 reference

14 August 2017

6

1 reference

14 August 2017

579-602

1 reference

New investigational antifungal agents for treating invasive fungal infections

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole for serious fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Review of the safety and efficacy of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibilit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro susceptibility of Candida dubliniensis to current and new antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro susceptibilities of zygomycetes to conventional and new antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro antifungal susceptibilities of Trichosporon species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of four novel triazoles against Scedosporium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro and in vivo activities of posaconazole against Coccidioides immitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro interactions of approved and novel drugs against Paecilomyces spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Risk of Fungemia Due to Rhodotorula and Antifungal Susceptibility Testing of Rhodotorula Isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Efficacy of ravuconazole in treatment of systemic murine histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole salvage treatment of invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Empirical antifungal therapy--new options, new tradeoffs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Subtle acquired renal injury as a mechanism of salt-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Emerging azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Posaconazole: clinical pharmacology and potential for management of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Treatment of Scedosporium apiospermum brain abscesses with posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Antifungal drugs in pregnancy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Breakthrough Candida infections in patients receiving voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Sinus zygomycosis in a patient receiving voriconazole prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant pat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Azole cross-resistance in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Caspofungin activity against clinical isolates of fluconazole-resistant Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.579

10.1517/13543784.15.6.579

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16732713